ArticleThe Lancet. Oncology2023

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.

Stephen R D Johnston et al.PubMed ↗Publisher ↗

No numbers read from the abstract.